We've documented real-life case studies for you, illustrating how the MyRBQM® Portal helped address common risks using the principles of risk-based quality management.
MyRBQM Portal V6.1.0 released! We're constantly working to improve your Risk-Based Quality Management experience. Download the summary of what has changed.
The report provides key statistics on the market status of the leading Risk-based Monitoring (RBM) Software market players and offers key trends and opportunities in the market.
MyRBQM® Portal's new Machine Learning predictive analytics model is far less sensitive to noise, it better generalizes data, and provides narrower CIs in long time series. Singular Spectrum Analysis is particularly valuable for long time series, as mostly observed in clinical trials.
We've created this "ask the experts" Q&A to provide clear responses to the questions that were most often asked by the forum's participants.
Frontiers Health Ecosystem Companies Fighting Back the COVID-19 Outbreak As the COVID-19 outbreak continues, it has become even more challenging for patients to seek in- person medical care and for healthcare providers (HCP) to guarantee community health services for people who may have symptoms [...]
Cyntegrity developed a special COVID-19 RACT that guides those involved in clinical trials on specific risks which may arise as a result of COVID-19, and how they can mitigate them. This special RACT is part of the COVID-19 rapid deployment pack for ad-hoc centralized monitoring.
We can help establish near real-time centralized monitoring, enable the use of "ad-hoc crisis management" Key Risk Indicators (KRIs), and mitigate patient safety and study quality risks.
This week Applied Clinical Trials published an interesting case study of the risk-based quality management learning curve. The provision of a set of training modules helped Merz Pharma to initiate a smooth RBQM rollout.
Adaptive and intelligent Risk Based Quality Management (RBQM) is a powerful strategy for rare disease research. One of the main benefits is that RBQM allows for patient-centric trial design that is uniquely tailored to the specific rare disease.
